Last reviewed · How we verify
Midazolam, IV
At a glance
| Generic name | Midazolam, IV |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY4268989 (MORF-057) in Healthy Participants (PHASE1)
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- The Impact of a Shared Decision-Making Intervention on Intraoperative Patient Experience During Elective Cesarean Delivery Under Spinal Anesthesia (NA)
- A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100) (PHASE1, PHASE2)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Prospective IR-led Sedation Feasibility (PHASE1, PHASE2)
- Propofol vs Remifentanil for Sedation in Gastroscopy (NA)
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Midazolam, IV CI brief — competitive landscape report
- Midazolam, IV updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI